委员会委托条例(EU) 2018/92,就用于人类医疗产品的药物警戒活动调整欧洲药品管理局的通胀率,修订条例(EU) No 658/2014

技术法规类型:欧盟Eurlex法规 来源:tbtmap

EURLEX ID:32018R0092

OJ编号:OJ L 17, 23.1.2018, p. 2–4

中文标题:委员会委托条例(EU) 2018/92,就用于人类医疗产品的药物警戒活动调整欧洲药品管理局的通胀率,修订条例(EU) No 658/2014

原文标题:Commission Delegated Regulation (EU) 2018/92 of 18 October 2017 amending Regulation (EU) No 658/2014 of the European Parliament and of the Council as regards the adjustment to the inflation rate of the amounts of the fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use (Text with EEA relevance. )

生效日期:2018-02-12

废止日期:9999-12-31

法规全文:查看欧盟官方文件

23.1.2018   

EN

Official Journal of the European Union

L 17/2


COMMISSION DELEGATED REGULATION (EU) 2018/92

of 18 October 2017

amending Regulation (EU) No 658/2014 of the European Parliament and of the Council as regards the adjustment to the inflation rate of the amounts of the fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 658/2014 of the European Parliament and of the Council of 15 May 2014 on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use (1), and in particular Article 15(6) thereof,

Whereas:

(1)

In accordance with Article 67(3) of Regulation (EC) No 726/2004 of the European Parliament and of the Council (2), the revenue of the European Medicines Agency consists of a contribution from the Union and fees paid by undertakings for obtaining and maintaining Union marketing authorisations and for other services provided by the Agency, or by the coordination group as regards the fulfilment of its tasks in accordance with Articles 107c, 107e, 107g, 107k and 107q of Directive 2001/83/EC of the European Parliament and of the Council (3).

(2)

The inflation rate of the Union, as published by the Statistical Office of the European Union, was 0,2 % for 2015 and 1,2 % for 2016. Taking into consideration the very low inflation rate in 2015, it was not considered justified to adjust, in accordance with Article 15(6) of Regulation (EU) No 658/2014, the amounts of the fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use. In view of the inflation rate of the Union for 2016, it is considered justified to adjust those amounts. A cumulative adjustment taking into account the inflation rates for 2015 and for 2016 should be applied.

(3)

For the sake of simplicity, the adjusted amounts should be rounded to the nearest EUR 10, with the exception of the annual fee for information technology systems and literature monitoring where the adjusted level should be rounded to the nearest EUR 1.

(4)

Fees laid down in Regulation (EU) No 658/2014 are due either at the date of the start of the respective procedure or, in the case of the annual fee for information technology systems and literature monitoring, on 1 July of every year. Consequently, the applicable amount will be determined by the due date of the fee and there is no need to set specific transitional provisions for pending procedures.

(5)

According to Article 15(6) of Regulation (EU) No 658/2014, where a delegated act adjusting the amounts of the fees laid down in Parts I to IV of the Annex to that Regulation enters into force before 1 July, the adjustments are to take effect as from 1 July, whereas where it enters into force after 30 June, the adjustments are to take effect from the date of entry into force of the delegated act.

(6)

The Annex to Regulation (EU) No 658/2014 should therefore be amended accordingly,

HAS ADOPTED THIS REGULATION:

Article 1

The Annex to Regulation (EU) No 658/2014 is amended as follows:

(1)

in Part I, point 1 is amended as follows:

(a)

‘EUR 19 500’ is replaced by ‘EUR 19 770’;

(b)

‘EUR 13 100’ is replaced by ‘13 290’;

(2)

in Part II, point 1 is amended as follows:

(a)

in the introductory sentence, ‘EUR 43 000’ is replaced by ‘EUR 43 600’;

(b)

point (a) is amended as follows:

(i)

‘EUR 17 200’ is replaced by ‘EUR 17 440’;

(ii)

‘EUR 7 280’ is replaced by ‘EUR 7 380’;

(c)

point (b) is amended as follows:

(i)

‘EUR 25 800’ is replaced by ‘EUR 26 160’;

(ii)

‘EUR 10 920’ is replaced by ‘11 070’;

(3)

in Part III, point 1 is amended as follows:

(a)

the first subparagraph is amended as follows:

(i)

‘EUR 179 000’ is replaced by ‘EUR 181 510’;

(ii)

‘EUR 38 800’ is replaced by ‘EUR 39 350’;

(iii)

‘EUR 295 400’ is replaced by ‘EUR 299 560’;

(b)

the second subparagraph is amended as follows:

(i)

in point (a), ‘EUR 119 333’ is replaced by ‘EUR 121 000’;

(ii)

in point (b), ‘EUR 145 200’ is replaced by ‘EUR 147 240’;

(iii)

in point (c), ‘EUR 171 066’ is replaced by ‘EUR 173 470’;

(iv)

in point (d), ‘EUR 196 933’ is replaced by ‘EUR 199 700’;

(c)

in the fourth subparagraph, point (b) is amended as follows:

(i)

‘EUR 1 000’ is replaced by ‘EUR 1 010’;

(ii)

‘EUR 2 000’ is replaced by ‘EUR 2 020’;

(iii)

‘EUR 3 000’ is replaced by ‘EUR 3 050’;

(4)

in point 1 of Part IV, ‘EUR 67’ is replaced by ‘EUR 68’.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. It shall apply from 12 February 2018.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 18 October 2017.

For the Commission

The President

Jean-Claude JUNCKER


(1)  OJ L 189, 27.6.2014, p. 112.

(2)  Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1).

(3)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67).


附件:

P020180428553893623493.pdf
P020180428553893752567.html

托管标准,您可以接收以下服务:

1 标准定期系统查新,若有最新版本,会以站内短信或邮件的形式通知用户;

2 随时在标准托管页面中查看到该条标准的最新状态;

3 若用户有在学习和科研中的需要,可以在标准托管页面中试阅标准;

4 企业如果需要上新产品,我院及时提供标准查询、采购等方面的支持;

5 为企业在标准制修订、企业良好行为创建以及标准化试点过程中遇到的困难,可联系我院指定相关专家负责进行指导帮助、提供政策咨询;

6 为企业提供标准化政策的解读、标准化知识的推广培训、标准自我公开声明、标准文献的免费查询、企业标准化体系建设等方面的标准化服务;

进入企业标准托管

您可以通过编辑查新模板,批量查询指定标准集的最新情况。我们会通过查询,向您展示您所查询标准的:

1. 准确的标准号及标准名称(我们通过人工智能技术对您提交的标准号进行自动纠正)

2. 标准的最新状态(现行、废止或未发布)

3. 若标准已废止并被新标准替代,会反馈被替代的标准

4. 若您已托管此标准,便可以实时跟踪这个标准的最新状态

标准查新 模板下载

您可以在这里检索全球超过140万条标准,支持上百个国内国际标准组织的标准查询。您也可以在这里检索国内各类国家、部委和地方的法律法规。

更多标准子库在持续建设中。

标准检索

标准资讯点击排行榜 全部

资讯标题点击

[[ n.title ]] [[ n.read ]]

大连标准化公共服务平台

版权:大连标准化研究院有限公司

地址:大连市中山区高原街56号

电话:0411-82740851

大连标准